BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
8.98
+0.08 (0.90%)
Sep 4, 2026, 4:00 PM EDT - Market closed
BridgeBio Oncology Therapeutics Employees
BridgeBio Oncology Therapeutics had 88 employees as of June 30, 2026. The number of employees increased by 26 or 41.94% compared to the same quarter last year.
Employees
88
Change
26
Growth
41.94%
Revenue / Employee
n/a
Profits / Employee
-$2,069,477
Market Cap
719.96M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 88 | 26 | 41.94% |
| Mar 31, 2026 | 106 | 44 | 70.97% |
| Dec 31, 2025 | 92 | 30 | 48.39% |
| Sep 30, 2025 | 81 | 19 | 30.65% |
| Mar 31, 2025 | 62 | - | - |
| Dec 31, 2024 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| Allogene Therapeutics | 152 |
| MapLight Therapeutics | 133 |
| Verastem | 102 |
| Assembly Biosciences | 73 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
BBOT News
- 6 days ago - BBOT to Participate in Upcoming Investor Healthcare Conferences - GlobeNewsWire
- 6 days ago - BridgeBio Oncology Therapeutics Registration statement: Registration filing - Filings
- 22 days ago - BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan - TheFly
- 27 days ago - BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 27 days ago - BridgeBio Oncology Therapeutics Earnings release: Q2 2026 - Filings
- 27 days ago - BridgeBio Oncology Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - BridgeBio Oncology initiated with an Overweight at JPMorgan - TheFly